论文部分内容阅读
目的探讨参芪扶正注射液与紫杉醇+顺铂(TP)方案联合治疗晚期卵巢癌的临床疗效。方法选取2010年3月至2014年10月间收治的80例卵巢癌患者,按照随机数字表法分为研究组(n=42)和对照组(n=38)。研究组患者给予参芪扶正注射液联合TP方案化疗,对照组患者给予常规的TP方案化疗。观察两组的临床治疗效果。结果研究组患者治疗有效率为81.0%,对照组为76.3%,差异无统计学意义(P<0.05)。治疗后两组患者的生活质量评分均较治疗前明显提升,且治疗后研究组生活质量评分高于对照组,差异有统计学意义(P<0.05)。研究组患者白细胞减少、胃肠道反应、脱发和恶心、呕吐不良反应的发生率低于对照组,差异均有统计学意义(均P<0.05)。结论对于晚期卵巢癌患者,在常规TP方案化疗基础上联合参芪扶正注射液治疗可以提高患者的生活质量,降低不良反应,值得临床应用与推广。
Objective To investigate the clinical efficacy of Shenqi Fuzheng injection combined with paclitaxel + cisplatin (TP) in the treatment of advanced ovarian cancer. Methods Eighty ovarian cancer patients who were treated between March 2010 and October 2014 were divided into study group (n = 42) and control group (n = 38) according to random number table. Patients in the study group were given Shenqi Fuzheng Injection combined with TP regimen chemotherapy, and patients in the control group were given conventional TP regimen chemotherapy. The clinical effects of the two groups were observed. Results The effective rate of treatment was 81.0% in the study group and 76.3% in the control group, with no significant difference (P <0.05). After treatment, the quality of life scores of the two groups were significantly improved compared with that before treatment, and the quality of life score of the study group was higher than that of the control group after treatment (P <0.05). The incidence of leukopenia, gastrointestinal reaction, alopecia and nausea and vomiting in study group were lower than those in control group (all P <0.05). Conclusions For patients with advanced ovarian cancer, the combination of Shenqi Fuzheng injection on the basis of routine TP regimen chemotherapy can improve the quality of life and reduce adverse reactions in patients with advanced ovarian cancer, which is worthy of clinical application and promotion.